NORMALISATION OF AIRFLOW LIMITATION IN ASTHMA: POST HOC ANALYSES OF TRIMARAN AND TRIGGER TRIALS

Abstract

In asthma, persistent airflow limitation (PAL) is associated with poorer control of the disease, lung function decline and exacerbations. In this study, the relationship between post‐salbutamol PAL at screening, airflow limitation (AL) during 52 weeks of treatment with extra-fine beclometasone dipropionate / formoterol fumarate / glycopyrronium (BDP / FF / G) versus BDP / FF and the risk of moderate/severe asthma exacerbations was evaluated using post hoc analysis. It was found that AL in asthma was associated with an increased exacerbation incidence. Inhaled triple therapy with extra-fine BDP / FF / G was more likely to normalise airflow. It was associated with a trend of a lower exacerbation rate than BDP / FF, particularly in the subgroup of patients in whom treatment was associated with airflow normalisation.